Leverkusen (pta022/09.08.2017/14:30) -
Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that the Company has recently completed an expansion of its U.S. subsidiary to strengthen its commercial operations and internal sales support services to support increasing momentum for Ameluz® in the U.S. market.
The Company has strategically assumed internal control of several key functions that previously have been assumed by Biofrontera's wholesaler. Taking these operations in-house will allow more timely reactions to customer needs and reduce cost in the long-term. These enhanced capabilities will allow Biofrontera to meet customer needs and keep pace with its rapidly expanding customer base.
Biofrontera will assume full responsibility of all health care provider support, including customer service and financial services to further support the commercialization of Ameluz®, at its Wakefield, MA office by establishing a dedicated team of experienced customer service professionals. Under this new structure, Biofrontera can now offer the highest level of support to dermatologists and patients in an efficient and cost-effective manner. The dedicated customer service team will provide extended hours and support for order entry, reimbursement assistance, invoicing, as well as personal customer support.
"We believe that customer loyalty is paramount to building a sustainable, high growth business," said Randall Wilhoite, COO of Biofrontera, Inc. "Along with a best in class product and an unrivaled sales force, we collectively hope to foster long lasting business relationships with our customers that in turn will provide our high quality treatment for actinic keratosis to more patients in the U.S."
Ameluz®, a topical prescription drug used in combination with the medical device BF-RhodoLED® for photodynamic therapy (PDT) treatment for actinic keratosis, a skin cancer precursor affecting about 10% of the entire Caucasian population, was commercially launched in October 2016 in the U.S.
Enquiries, please contact:
Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0
IR Germany: Brainwell Asset Solutions
+49 (0) 152 08931514
IR UK: Seton Services
+44(0) 20 7729 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas
Biofrontera AG is a biopharmaceutical company specializing in the development, sale and distribution of dermatological drugs and medical cosmetics. The Leverkusen, Germany-based company, which has approximately 100 employees worldwide, develops and distributes innovative products for the care, protection and treatment of the skin. Biofrontera's combination lead product is topical prescription drug Ameluz® and medical device BF-RhodoLED® for the photodynamic therapy (PDT) treatment of superficial skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the U.S. since 2016. The Company also markets the Belixos® dermocosmetics series in the EU, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German, founder-led pharmaceutical company to obtain both EU and U.S. approval for a medical drug it has developed itself. The Biofrontera Group was established in 1997 by current CEO, Prof. Dr. Hermann Lübbert, and is listed on the Frankfurt Stock Exchange (Prime Standard).
This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.